コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 atment for patients with locally advanced or metastatic non-small-cell lung cancer.
2 xel improved survival in locally advanced or metastatic non-small-cell lung cancer.
3 d from type II cells and >60% of primary and metastatic non-small cell lung cancers.
5 d adults (aged >/=18 years) with advanced or metastatic non-small-cell lung cancer from 75 centres in
7 irculating tumor cells from 27 patients with metastatic non-small-cell lung cancer (median number, 74
9 gnosis and goals of therapy in patients with metastatic non-small-cell lung cancer (NSCLC) and to exa
10 care soon after diagnosis for patients with metastatic non-small-cell lung cancer (NSCLC) is associa
11 rogression after first-line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs mos
12 early palliative care (EPC) in patients with metastatic non-small-cell lung cancer (NSCLC) was observ
13 y of 27 assessable patients with advanced or metastatic non-small-cell lung cancer (NSCLC), the respo
14 enhances antitumor immunity in patients with metastatic non-small-cell lung cancer (NSCLC), we conduc
15 64-year-old woman receives the diagnosis of metastatic non-small-cell lung cancer (NSCLC), which has
16 lus concurrent chemotherapy in patients with metastatic non-small-cell lung cancer (NSCLC), with prec
23 nrolled patients who had locally advanced or metastatic non-small-cell lung cancer, progression after
24 evidence from a phase III RCT, patients with metastatic non-small-cell lung cancer should be offered
25 domly assigned patients with newly diagnosed metastatic non-small-cell lung cancer to receive either
26 cetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who had been pretr
27 bserved in a patient with previously treated metastatic non-small cell lung cancer, who remained on s
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。